Finding cancer’s signal, earlier.

One accessible device. A new level of diagnostic accuracy. DNA, methylated DNA and protein biomarkers, measured together in a single test.

Partner with us How it works

100sof DNA and protein targets measured in one test

<30 minfrom raw sample to actionable result

1 → manynodes: from a GP surgery to a central lab

Our mission

Catch the cancers other tests miss.

Every year, millions of cancer patients receive a late or incorrect diagnosis, leading to invasive, unnecessary treatments that devastate lives and drain healthcare resources.

Our fully automated, sample-to-answer device will require minimal training, making it simple enough for staff at a GP surgery or pharmacy to use, yet engineered to scale for massive volumes in centralised labs.

We aim to deliver more accurate answers in an affordable way and save more than 100,000 lives every year.

How it works

From sample to answer
in three steps.

1 · Add the sample

A single blood sample goes into an ultra-simple consumable. No sample preparation or specialist training.

2 · Measure everything at once

Hundreds of DNA, methylated DNA and protein biomarkers are detected and quantified in parallel, in one run.

3 · Get a clear answer

Results from all three biomarker classes are combined into one actionable result, in under 30 minutes.

DNAGenetic markers associated with cancer.

Methylated DNAEpigenetic changes associated with cancer.

ProteinCirculating proteins that reflect how the body is responding to a tumour.

DNA + methylated DNA + protein, combined in one test: catching cancers that single-biomarker tests miss.

Technology

No more trade-off between
accuracy and access.

Current cancer screening tools force an unacceptable compromise: they are either too expensive for widespread use, or too limited in the biomarkers they measure, resulting in missed diagnoses and false alarms. 4fold is breaking that paradigm.

Ultra-multiplexed chemistry

Simultaneous detection and quantification of hundreds of nucleic acid or protein targets in parallel, delivering vastly more data than traditional molecular diagnostics.

Cost-effective hardware

Consumer-electronics supply chains and a modular design make a rugged, highly accessible instrument that lowers the barrier to entry for clinics and labs.

Frictionless workflow

A true sample-to-answer system. An ultra-simple consumable, fully automated from raw sample, with actionable results in under 30 minutes.

Scalability

One node. Or many.

Every instrument is a self-contained node that can operate entirely on its own or cluster together for high throughput.

Point of care

A single node is compact enough for a GP surgery, pharmacy or clinic, for rapid on-site testing with immediate results.

Centralised testing

Nodes stack into a high-throughput system for clinical labs. Units attach in seconds, sharing power and data with no complex wiring.

Roadmap

Where we are.

Our path from the lab to clinics and pharmacies.

Proof of conceptIn progress · 2026

Pre-prototypePlanned · 2028

PrototypePlanned · 2030

Analytical validationPlanned · 2031

Clinical studiesPlanned · 2032–33

Regulatory approval & launchPlanned · 2034

Team

Who we are.

Ollie Miller

Co-founder

Drives the core technology: detection chemistry and hardware architecture. PhD in Biochemical Engineering and 15 years translating R&D into commercial products, including leading new sequencing platform projects at Illumina.

Duncan Brett